GlaxoSmithKline (LON:GSK) Stock Rating Reaffirmed by UBS Group

UBS Group reissued their neutral rating on shares of GlaxoSmithKline (LON:GSK) in a research report report published on Friday morning, ThisIsMoney.Co.Uk reports.

GSK has been the subject of several other reports. Credit Suisse Group assumed coverage on Regeneron Pharmaceuticals in a research note on Monday, May 20th. They set a neutral rating and a $336.00 target price for the company. Kepler Capital Markets raised their target price on GlaxoSmithKline from GBX 1,440 ($18.82) to GBX 1,540 ($20.12) and gave the company a hold rating in a research note on Tuesday, June 11th. Barclays set a $330.00 target price on Thermo Fisher Scientific and gave the company a buy rating in a research note on Monday, July 15th. Deutsche Bank restated a buy rating and set a $80.00 target price on shares of Bayerische Motoren Werke in a research note on Monday, July 8th. Finally, Jefferies Financial Group restated a buy rating and set a C$15.00 target price on shares of Aphria in a research note on Friday, May 24th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and five have given a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of GBX 1,536.87 ($20.08).

Shares of GlaxoSmithKline stock opened at GBX 1,654.60 ($21.62) on Friday. The firm’s 50-day simple moving average is GBX 1,603.27. The company has a quick ratio of 0.45, a current ratio of 0.72 and a debt-to-equity ratio of 942.07. The firm has a market capitalization of $82.53 billion and a P/E ratio of 21.08. GlaxoSmithKline has a 1-year low of GBX 1,408.80 ($18.41) and a 1-year high of GBX 1,658 ($21.66).

The company also recently declared a dividend, which was paid on Thursday, July 11th. Investors of record on Thursday, May 16th were paid a GBX 19 ($0.25) dividend. The ex-dividend date was Thursday, May 16th. This represents a yield of 1.22%. GlaxoSmithKline’s dividend payout ratio (DPR) is 0.97%.

In other news, insider Manvinder Singh Banga purchased 458 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was acquired at an average cost of GBX 1,568 ($20.49) per share, for a total transaction of £7,181.44 ($9,383.82). Insiders purchased 482 shares of company stock valued at $755,935 over the last quarter.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Read More: How to interpret the current ratio

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit